AbbVie to buy Apogee Therapeutics for $10.9B in immunology push
What's the deal? AbbVieDealroom has a profile for this one. Try Dealroom → has agreed to acquire Apogee Therapeutics for approximately $10.9 billion — $135.11 per share in cash — in a bid to deepen its immunology pipeline. The deal gives AbbVie control of zumilokibart, a late-stage antibody targeting IL-13 in development for atopic dermatitis (eczema), along with a broader pipeline of clinical-stage assets in inflammatory and immunological diseases, including asthma.
Apogee's lead candidate has impressed analysts in recent phase 2 updates. Cross-trial comparisons suggest zumilokibart can match or beat the efficacy of Eli LillyDealroom has a profile for this one. Try Dealroom →'s Ebglyss and SanofiDealroom has a profile for this one. Try Dealroom →/RegeneronDealroom has a profile for this one. Try Dealroom →'s Dupixent — both of which also target IL-13 — while reducing injection burden to once every three or six months.
The boards of both companies unanimously approved the transaction, which is expected to close in Q3 2026 pending shareholder and regulatory approvals.
Why now? AbbVie has built its immunology franchise around Skyrizi and Rinvoq, but the atopic dermatitis market is heating up. The company sees "mega-blockbuster peak sales potential" across Apogee's pipeline and wants to extend its clinical presence into respiratory diseases like asthma through Apogee's combination candidates.
Apogee's pipeline also includes APG273, a long-acting combination targeting both IL-13 and thymic stromal lymphopoietin (TSLP) in development for asthma — an area where AbbVie currently lacks a significant footprint.
What could go wrong? Zumilokibart is still in late-phase development, not yet approved. Phase 3 results could disappoint, and the competitive landscape is crowded — Dupixent is already entrenched, and Lilly's Ebglyss is gaining ground. Paying $10.9 billion for a pre-revenue biotech carries meaningful execution risk.
BMO Capital Markets analysts noted the deal "fits naturally" with AbbVie's existing portfolio, but realising the drug's commercial potential will depend on navigating a market where established therapies already have a head start.
The signal: Big pharma continues to pay premium prices for promising immunology assets, especially those that can differentiate on convenience — like less frequent dosing. AbbVie's bet reflects a broader industry conviction that the next generation of biologics in atopic dermatitis and asthma still holds billions in untapped value, even as incumbents dominate today's market.
Robert A. Michael, AbbVie's chairman and chief executive officer, framed the deal as a natural extension of two decades of immunology leadership: "Apogee's pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need."
Read more: AbbVie · BioPharma Dive · Fierce Biotech
